Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Severe Obstructive Sleep Apnea Doubles Risk of Heart Attack Death

XTALKS VITALS NEWS

Sleep Apnea

A recent study published in the American Heart Association’s (AHA) journal, Circulation, found that both moderate and severe forms of sleep apnea were associated with a higher risk of cardiovascular disease.

Share this!

February 9, 2017 | by Sarah Hand, M.Sc.

February is American Heart Month, and according to the National Healthy Sleep Awareness Project, leaving severe obstructive sleep apnea untreated raises an individual’s risk of suffering a fatal heart attack. In order to raise public awareness of this risk, the associations – in partnership with the American Academy of Sleep Medicine (AASM), the Centers for Disease Control and Prevention (CDC) and the Sleep Research Society (SRS) – are launching an ad campaign called “Sleep Apnea Hurts Hearts.”

A recent study published in the American Heart Association’s (AHA) journal, Circulation, found that both moderate and severe forms of sleep apnea were associated with a higher risk of cardiovascular disease. Treatment for sleep apnea often involves the use of a continuous positive airway pressure (CPAP) device.



“Obstructive sleep apnea is a dangerous disease that can severely damage your heart if left untreated,” said Dr. Ronald Chervin, president of the AASM and a spokesperson for the National Healthy Sleep Awareness Project. “With millions of sufferers remaining undiagnosed, it is critical to raise nationwide awareness about obstructive sleep apnea so that it can be treated with CPAP therapy, which can reduce the risk of cardiovascular death.”

In the context of the ad campaign, the word HEARTS is used as an acronym which names all of the negative health consequences of uncontrolled obstructive sleep apnea. The condition increases the risk of heart failure, elevated blood pressure, atrial fibrillation, resistant hypertension, type 2 diabetes and stroke.

“It is clear that untreated, severe obstructive sleep apnea may have a devastating impact on heart health,” said Dr. Janet B. Croft, senior chronic disease epidemiologist in CDC's Division of Population Health. “Anyone who has symptoms of sleep apnea such as loud snoring in addition to obesity and a heart problem or high blood pressure should discuss their risk for sleep apnea with their doctor.”

Obstructive sleep apnea is characterized by the collapse of the upper airway during sleep, and affects almost 30 million Americans. Obesity, high blood pressure, snoring and fatigue are all risk factors and warning signs of sleep apnea, according to the National Healthy Sleep Awareness Project.


Keywords: Sleep Apnea, Heart Attack, Heart Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News


PTC to Acquire Marathon’s Recently Approved Duchenne Muscular Dystrophy Drug

March 17, 2017 - Amid a drug pricing controversy, PTC Therapeutics has agreed to buy Marathon Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug, Emflaza.

Featured In: Pharmaceutical News


Memphis Meats Produces World’s First Poultry from Animal Cells

March 17, 2017 - Silicon Valley-based food manufacturing company, Memphis Meats, has produced the world’s first “clean poultry” by growing chicken and duck cells outside the animals.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.